-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XB-002 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XB-002 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XB-002 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2023’, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Huntington Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Huntington Disease - Drugs In Development, 2023’, provides an overview of the Huntington Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Small Molecule For Drug Overdose And Drug Toxicity in Drug Toxicity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Small Molecule For Drug Overdose And Drug Toxicity in Drug Toxicity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Small Molecule For Drug Overdose And...
-
Product Insights
Urinary Catheters Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
Urinary Catheters Pipeline Market Report Overview A Urinary Catheter is a tube system to drain and collect urine from the bladder. These are used to manage urinary incontinence and urinary retention in both men and women. The Urinary Catheters pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed...
-
Product Insights
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha Synuclein Drugs Development Market Report Overview Alpha-synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It...
-
Product Insights
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Small Molecule for Drug Overdose and Drug Toxicity
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Small Molecule for Drug Overdose and Drug Toxicity Drug Details Lipid rescue therapy (LRT)...